Lingyi Biotech's LY-M001 Injection Honored as 'Rare Disease Drug with Highest Industry Attention' at the 2024 China Biopharma Innovation Leaders List
Lingyi Biotech
Gene Therapy Drug Developer
On December 17, 2024, the "2024 (5th) China Biomedical Industry Chain Innovation Leaderboard" was officially released.LY-M001 Injection from Lingyi Biotech, a company in the Xingbei FTI No.1 Park, wins "Rare Disease Drug of the Year Industry Attention Award". This honor is not only an affirmation of Lingyi Biotech's work in the field of rare disease treatment, but also a recognition of the team's relentless efforts and innovative spirit.
"China Biomedical Industry Chain Innovation风云榜 (Innovation Ranking)" was initiated by the China Biomedical Industry Chain Innovation and Transformation Consortium (CBIITA Consortium) and, since its release in 2020, has become one of the most authoritative and influential selection events in the industry. The ranking, based on multi-dimensional authoritative data analysis and expert perspective verification, combines objective data with expert insights to establish industry benchmarks, stimulate innovation potential, and foster an innovative environment.
LY-M001 Injection is a significant research achievement by Lingyi Biotech in the field of rare diseases, marking a major breakthrough for the company in the treatment of rare diseases. Lingyi Biotech will continue to uphold the concept of "patient-centeredness," increase R&D investment, and promote the development and market launch of more innovative drugs to meet the unmet medical needs of patients with rare diseases.
Lingyi Biotech was founded in February 2021 and is a global leading company in the development of drugs for monogenic inherited diseases. The company is committed to original innovation, focusing on disease areas with urgent clinical needs such as metabolism, the central nervous system, and ophthalmology. Starting with key technologies like animal models of genetic diseases, it provides patients with one-time solutions.
In the field of rare diseases, the company boasts an internationally top-tier team in gene therapy discovery, research and development, and industrialization. It also possesses a globally leading platform for the creation and validation of rare disease animal models, addressing the challenge of lacking effective animal models in rare disease research. The company is committed to the R&D and industrialization of FIC gene therapy pipelines, leveraging genes to create value and improve human health.
About SimbayPark
Shanghai FT1 Life Science Park (Abbreviation"Simbay Park, Star North Free Trade Zone No.1 Project" is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the Star North Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "Free Trade + Bonded" outward-oriented economic zone advantages, and by gathering the entire industry chain service resources of CRO+CDMO+CSO+EHS in the biopharmaceutical field, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, it provides enterprises with truly in-depth technical incubation in the medical industry. It serves as a steward for the transformation of corporate technological achievements, and is committed to building an international biopharmaceutical industry innovation and entrepreneurship base.
